Literature DB >> 16618719

Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice.

Mark Katzenellenbogen1, Orit Pappo, Hila Barash, Naama Klopstock, Lina Mizrahi, Devorah Olam, Jasmine Jacob-Hirsch, Ninette Amariglio, Gidi Rechavi, Leslie Ann Mitchell, Ron Kohen, Eytan Domany, Eithan Galun, Daniel Goldenberg.   

Abstract

Molecular events preceding the development of hepatocellular carcinoma were studied in the Mdr2-knockout (Mdr2-KO) mice. These mice lack the liver-specific P-glycoprotein responsible for phosphatidylcholine transport across the canalicular membrane. Portal inflammation ensues at an early age followed by hepatocellular carcinoma development after the age of 1 year. Liver tissue samples of Mdr2-KO mice in the early and late precancerous stages of liver disease were subjected to histologic, biochemical, and gene expression profiling analysis. In an early stage, multiple protective mechanisms were found, including induction of many anti-inflammatory and antioxidant genes and increase of total antioxidant capacity of liver tissue. Despite stimulation of hepatocyte DNA replication, their mitotic activity was blocked at this stage. In the late stage of the disease, although the total antioxidant capacity of liver tissue of Mdr2-KO mice was normal, and inflammation was less prominent, many protective genes remained overexpressed. Increased mitotic activity of hepatocytes resulted in multiple dysplastic nodules, some of them being steatotic. Expression of many genes regulating lipid and phospholipid metabolism was distorted, including up-regulation of choline kinase A, a known oncogene. Many other oncogenes, including cyclin D1, Jun, and some Ras homologues, were up-regulated in Mdr2-KO mice at both stages of liver disease. However, we found no increase of Ras activation. Our data suggest that some of the adaptive mechanisms induced in the early stages of hepatic disease, which protect the liver from injury, could have an effect in hepatocarcinogenesis at later stages of the disease in this hepatocellular carcinoma model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618719     DOI: 10.1158/0008-5472.CAN-05-2937

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

Review 1.  Characterization of animal models for primary sclerosing cholangitis (PSC).

Authors:  Peter Fickert; Marion J Pollheimer; Ulrich Beuers; Carolin Lackner; Gideon Hirschfield; Chantal Housset; Verena Keitel; Christoph Schramm; Hanns-Ulrich Marschall; Tom H Karlsen; Espen Melum; Arthur Kaser; Bertus Eksteen; Mario Strazzabosco; Michael Manns; Michael Trauner
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

Review 2.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

3.  Hydrophilic bile acids prevent liver damage caused by lack of biliary phospholipid in Mdr2-/- mice.

Authors:  Renxue Wang; Jonathan A Sheps; Lin Liu; Jun Han; Patrick S K Chen; Jason Lamontagne; Peter D Wilson; Ian Welch; Christoph H Borchers; Victor Ling
Journal:  J Lipid Res       Date:  2018-11-11       Impact factor: 5.922

4.  A critical role for ceramide synthase 2 in liver homeostasis: II. insights into molecular changes leading to hepatopathy.

Authors:  Yael Pewzner-Jung; Ori Brenner; Svantje Braun; Elad L Laviad; Shifra Ben-Dor; Ester Feldmesser; Shirley Horn-Saban; Daniela Amann-Zalcenstein; Calanit Raanan; Tamara Berkutzki; Racheli Erez-Roman; Oshrit Ben-David; Michal Levy; Dorin Holzman; Hyejung Park; Abraham Nyska; Alfred H Merrill; Anthony H Futerman
Journal:  J Biol Chem       Date:  2010-01-28       Impact factor: 5.157

5.  Extended exposure to dietary melatonin reduces tumor number and size in aged male mice.

Authors:  Edward H Sharman; Kaizhi G Sharman; Stephen C Bondy
Journal:  Exp Gerontol       Date:  2010-09-16       Impact factor: 4.032

6.  Innovative immunohistochemistry identifies MMP-9 expressing macrophages at the invasive front of murine HCC.

Authors:  Martin Roderfeld; Timo Rath; Frank Lammert; Christian Dierkes; Jürgen Graf; Elke Roeb
Journal:  World J Hepatol       Date:  2010-05-27

Review 7.  Mouse models for liver cancer.

Authors:  Latifa Bakiri; Erwin F Wagner
Journal:  Mol Oncol       Date:  2013-02-05       Impact factor: 6.603

8.  Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma.

Authors:  Isaac S Chan; Cynthia D Guy; Yuping Chen; Jiuyi Lu; Marzena Swiderska-Syn; Gregory A Michelotti; Gamze Karaca; Guanhua Xie; Leandi Krüger; Wing-Kin Syn; Blair R Anderson; Thiago A Pereira; Steve S Choi; Albert S Baldwin; Anna Mae Diehl
Journal:  Cancer Res       Date:  2012-10-12       Impact factor: 12.701

9.  Rhomboid domain-containing protein 3 is a negative regulator of TLR3-triggered natural killer cell activation.

Authors:  Juan Liu; Shuxun Liu; Meng Xia; Sheng Xu; Chunmei Wang; Yan Bao; Minghong Jiang; Yue Wu; Tian Xu; Xuetao Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

10.  The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma.

Authors:  Lika Gamaev; Lina Mizrahi; Tomer Friehmann; Nofar Rosenberg; Orit Pappo; Devorah Olam; Evelyne Zeira; Keren Bahar Halpern; Stefano Caruso; Jessica Zucman-Rossi; Jonathan H Axelrod; Eithan Galun; Daniel S Goldenberg
Journal:  Oncogene       Date:  2020-10-22       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.